Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Clinical trial NCT04186871 · COMPLETED

Trial details

NCT number: NCT04186871
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Autoimmune Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome

Start date: 2020-01-07
Primary completion: 2022-12-05
Enrollment: 119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.